Literature DB >> 1981148

Activation of tat-defective human immunodeficiency virus by ultraviolet light.

M R Sadaie1, E Tschachler, K Valerie, M Rosenberg, B K Felber, G N Pavlakis, M E Klotman, F Wong-Staal.   

Abstract

Ultraviolet light (UV) is known to cause activation of gene expression from the human immunodeficiency virus type 1 (HIV-1) promoter. To address the question of whether tat-defective HIV-1 provirus could be rescued by UV irradiation we examined its effect on HeLa cells containing integrated proviruses with tat mutations. Exposure of these cells to an optimal dose of UV resulted in the production of infectious viruses. The degree of UV activation and reversion to infectious virus appeared to depend on the nature of the original tat mutation. Two of the mutants required cocultivation with tat-expressing cells to fully generate replication competent viruses, while a third mutant required only cocultivation with H9 cells. Sequencing of cDNA from cells infected with this last mutant demonstrated that the parental mutant sequence was retained and that genotypic revertants to the wild-type as well as new mutant sequences were generated. These results suggest that tat-defective HIV-1 provirus can be activated by UV and can subsequently revert to wild-type virus. This study raises the possibility that UV exposure of immune cells in the skin plays a role in the activation of defective HIV-1 in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1981148

Source DB:  PubMed          Journal:  New Biol        ISSN: 1043-4674


  17 in total

1.  Rapid activation and subsequent down-regulation of the human immunodeficiency virus type 1 promoter in the presence of Tat: possible mechanisms contributing to latency.

Authors:  C M Drysdale; G N Pavlakis
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

2.  Potential of Radiation-Induced Cellular Stress for Reactivation of Latent HIV-1 and Killing of Infected Cells.

Authors:  Sergey Iordanskiy; Fatah Kashanchi
Journal:  AIDS Res Hum Retroviruses       Date:  2016-02       Impact factor: 2.205

3.  UV activation of human immunodeficiency virus gene expression in transgenic mice.

Authors:  J Vogel; M Cepeda; E Tschachler; L A Napolitano; G Jay
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

4.  Identification of nucleolin and nucleophosmin as genotoxic stress-responsive RNA-binding proteins.

Authors:  Chonglin Yang; Dony A Maiguel; France Carrier
Journal:  Nucleic Acids Res       Date:  2002-05-15       Impact factor: 16.971

5.  Novel biopanning strategy to identify epitopes associated with vaccine protection.

Authors:  Barbara C Bachler; Michael Humbert; Brisa Palikuqi; Nagadenahalli B Siddappa; Samir K Lakhashe; Robert A Rasmussen; Ruth M Ruprecht
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

6.  Induction of RNA-binding proteins in mammalian cells by DNA-damaging agents.

Authors:  F Carrier; A Gatignol; M C Hollander; K T Jeang; A J Fornace
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

Review 7.  Genetic regulation of human immunodeficiency virus.

Authors:  K Steffy; F Wong-Staal
Journal:  Microbiol Rev       Date:  1991-06

8.  IRF-1 is required for full NF-kappaB transcriptional activity at the human immunodeficiency virus type 1 long terminal repeat enhancer.

Authors:  Marco Sgarbanti; Anna L Remoli; Giulia Marsili; Barbara Ridolfi; Alessandra Borsetti; Edvige Perrotti; Roberto Orsatti; Ramona Ilari; Leonardo Sernicola; Emilia Stellacci; Barbara Ensoli; Angela Battistini
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

9.  Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines.

Authors:  L Buonaguro; G Barillari; H K Chang; C A Bohan; V Kao; R Morgan; R C Gallo; B Ensoli
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

10.  Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation.

Authors:  B Ensoli; L Buonaguro; G Barillari; V Fiorelli; R Gendelman; R A Morgan; P Wingfield; R C Gallo
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.